Skip to content
Biophytis
LIVE HEALTHIER LONGER
Biophytis
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
    • Recruitment
  • Our Science
    • Sarconeos (BIO101)
    • Posters & Publications
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
    • Macuneos (BIO201)
    • Posters & Publications
  • Pipeline
    • Key programs milestones
    • COVID-19: COVA clinical program
    • Sarcopenia: SARA clinical program
    • Duchenne Muscular Dystrophy: MYODA clinical program
    • Age-related Macular Degeneration: MACA clinical program
  • Investors
    • Live Stock Price
    • Corporate Presentation
    • General Meetings
      • 2022
      • 2021
      • 2020
    • AMF Regulated Information
    • SEC Filings
    • Financial Calendar
  • News
    • Press Releases
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
    • Biophytis in Media
  • Recruitment
  • Contact
    • Contact
    • Contact Information
    • Legal information
  • LinkedIn
  • Twitter
  • FR
  • EN
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
    • Recruitment
  • Our Science
    • Sarconeos (BIO101)
    • Posters & Publications
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
    • Macuneos (BIO201)
    • Posters & Publications
  • Pipeline
    • Key programs milestones
    • COVID-19: COVA clinical program
    • Sarcopenia: SARA clinical program
    • Duchenne Muscular Dystrophy: MYODA clinical program
    • Age-related Macular Degeneration: MACA clinical program
  • Investors
    • Live Stock Price
    • Corporate Presentation
    • General Meetings
      • 2022
      • 2021
      • 2020
    • AMF Regulated Information
    • SEC Filings
    • Financial Calendar
  • News
    • Press Releases
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
    • Biophytis in Media
  • Recruitment
  • Contact
    • Contact
    • Contact Information
    • Legal information
  • LinkedIn
  • Twitter
  • FR
  • EN

Press Releases

March 11, 2016

BIOPHYTIS receives positive scientific advice on SARCOB BIO101 clinical development plan from Belgian regulatory authority. Download the Press Release

Read the press release »

January 20, 2016

American LifeSci Capital initiates coverage of Biophytis stock. Téléchargez le communiqué de presse. Téléchargez le communiqué de presse

Read the press release »

January 07, 2016

Biophytis to present at the Biotech Showcase conference run parallel to the JP Morgan Healthcare Conference (San Francisco, January 11-13, 2016). Read the Press Release

Read the press release »

December 11, 2015

Biophytis Appoints of Roger A. Fielding, Ph.D., as a Scientific Consultant for Company’s SARCOB Clinical Development Program. Download the Press Release

Read the press release »

December 04, 2015

Half-year results for 2015. Download the Press Release

Read the press release »

December 01, 2015

Biophytis Appoints Pierre J. Dilda as Director of Research. Read the Press Release

Read the press release »

November 26, 2015

Biophytis to present preclinical proof of concept for Sarcob to treat sarcopenic obesity at SCWD on December 4th. Download the Press Release

Read the press release »

November 17, 2015

Biophytis establishes Boston subsidiary to accelerate clinical development. Download the Press Release

Read the press release »

November 10, 2015

BIOPHYTIS Invited to Attend the Jefferies 2015 Global Healthcare Conference. Read the press release

Read the press release »

September 21, 2015

BIOPHYTIS initiates the clinical batches production of BIO101, the first step in the ongoing phase 2b trial in the sarcopenic obesity. Click here to download the Press Release

Read the press release »
« Previous Page1 … Page20 Page21 Page22 Page23 Next »
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
    • Recruitment
  • Our Science
    • Sarconeos (BIO101)
    • Posters & Publications
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
    • Macuneos (BIO201)
    • Posters & Publications
  • Pipeline
    • Key programs milestones
    • COVID-19: COVA clinical program
    • Sarcopenia: SARA clinical program
    • Duchenne Muscular Dystrophy: MYODA clinical program
    • Age-related Macular Degeneration: MACA clinical program
  • Investors
    • Live Stock Price
    • Corporate Presentation
    • General Meetings
      • 2022
      • 2021
      • 2020
    • AMF Regulated Information
    • SEC Filings
    • Financial Calendar
  • News
    • Press Releases
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
    • Biophytis in Media
  • Recruitment
  • Contact
    • Contact
    • Contact Information
    • Legal information
  • LinkedIn
  • Twitter
  • FR
  • EN
BIOPHYTIS
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
  • Our Science
    • Sarconeos (BIO101)
    • Posters & Publications
    • Macuneos (BIO201)
    • Posters & Publications
  • Investors
    • Financial Calendar
    • AMF Regulated Information
  • Pipeline
    • Key programs milestones
    • COVID-19: COVA clinical program
    • Sarcopenia: SARA clinical program
    • Duchenne Muscular Dystrophy: MYODA clinical program
    • Age-related Macular Degeneration: MACA clinical program
  • Contact
    • Contact Information
© Biophytis 2006-2022 - Mentions Légales
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
Footer Colonne 1 - Anglais
Go to Top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok